selectIon, Inc.
selectION Therapeutics' si-544 is a first-in-class Kv1.3 blocker and the first disease modifying treatment for T cell autoimmunity. Autoimmunity affects millions worldwide, but current treatments leave the root cause untouched. si-544 is the first therapy to safely and selectively deactivate disease-causing T cells, while preserving immune competence.
Funding history
About selectIon, Inc.
How much funding has selectIon, Inc. raised?
selectIon, Inc. has raised $5.4M in total funding. The most recent round was Series A.
Where is selectIon, Inc. headquartered?
selectIon, Inc. is headquartered in San Diego, CA.
What does selectIon, Inc. do?
selectION Therapeutics' si-544 is a first-in-class Kv1.3 blocker and the first disease modifying treatment for T cell autoimmunity. Autoimmunity affects millions worldwide, but current treatments leave the root cause untouched. si-544 is the first therapy to safely and selectively deactivate disease-causing T cells, while preserving immune competence.
What problem does selectIon, Inc. solve?
Current autoimmune disease treatments rely on broad immunosuppression that manages symptoms but leaves the root cause untouched, forcing patients into a lifetime of treatment and immunosuppression-related risk.
What's selectIon, Inc.'s solution?
selectION is developing si-544, a drug that selectively blocks the Kv1.3 potassium channel to deactivate disease-causing T cells while preserving the rest of the immune system.
What makes selectIon, Inc. different?
The company calls si-544 the first-in-class Kv1.3 blocker and the first safe and effective one in 40+ years of research on this target, with potential application across 80+ autoimmune indications.
What makes selectIon, Inc. notable?
Founded by Andreas Klostermann in 2017, this autoimmune-disease biotech has raised roughly $36M (including a $4.1M Series A) from investors such as Global Source Ventures and SDL Ventures, and is led by CEO Antonius Schuh, a veteran pharma executive.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.